Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bristol-Myers Squibb Company or Viatris Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bristol-Myers Squibb Company and Viatris Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Bristol-Myers Squibb Company and Viatris Inc.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Latest Pharmaceuticals and Bristol-Myers Squibb Company, Viatris Inc. Stock News

As of September 2, 2026, Bristol-Myers Squibb Company had a $138.2 billion market capitalization, compared to the Pharmaceuticals median of $674.0 million. Bristol-Myers Squibb Company’s stock is up 25.4% in 2026, up 0.1% in the previous five trading days and up 42.71% in the past year.

Currently, Bristol-Myers Squibb Company’s price-earnings ratio is 14.9. Bristol-Myers Squibb Company’s trailing 12-month revenue is $49.2 billion with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was 5.7%. Analysts expect adjusted earnings to reach $6.949 per share for the current fiscal year. Bristol-Myers Squibb Company currently has a 3.7% dividend yield.

As of September 2, 2026, Viatris Inc. had a $19.6 billion market cap, putting it in the 86th percentile of all stocks. Viatris Inc.’s stock is up 37.3% in 2026, up 1.4% in the previous five trading days and up 61.93% in the past year.

Currently, Viatris Inc. does not have a price-earnings ratio. Viatris Inc.’s trailing 12-month revenue is $14.7 billion with a -2.8% net profit margin. Year-over-year quarterly sales growth most recently was 4.9%. Analysts expect adjusted earnings to reach $2.501 per share for the current fiscal year. Viatris Inc. currently has a 2.8% dividend yield.

How We Compare Bristol-Myers Squibb Company and Viatris Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bristol-Myers Squibb Company and Viatris Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bristol-Myers Squibb Company and Viatris Inc. Stock Value Grades

Company	Ticker	Value
Bristol-Myers Squibb Company	BMY	C
Viatris Inc.	VTRS	A

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Bristol-Myers Squibb Company has a Value Score of 51, which is Average. Viatris Inc. has a Value Score of 84, which is Deep Value.

The Value Stock Winner: Viatris Inc.

As you can clearly see from the Value Grade breakdown above, Viatris Inc. is considered to have better value than Bristol-Myers Squibb Company. For investors who focus solely on a company’s valuation, Viatris Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Bristol-Myers Squibb Company and Viatris Inc. Growth Grades

Company	Ticker	Growth
Bristol-Myers Squibb Company	BMY	C
Viatris Inc.	VTRS	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Bristol-Myers Squibb Company has a Growth Score of 43, which is Average. Viatris Inc. has a Growth Score of 32, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Bristol-Myers Squibb Company or Viatris Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bristol-Myers Squibb Company or Viatris Inc. is the better investment when it comes to sustainable growth.

Bristol-Myers Squibb Company and Viatris Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Bristol-Myers Squibb Company	BMY	B
Viatris Inc.	VTRS	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Bristol-Myers Squibb Company has a Earnings Estimate Score of 77, which is Positive. Viatris Inc. has a Earnings Estimate Score of 73, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both Bristol-Myers Squibb Company and Viatris Inc. have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether Bristol-Myers Squibb Company or Viatris Inc. is a better fit.

Other Bristol-Myers Squibb Company and Viatris Inc. Grades

In addition to Estimate Revisions, Growth and Value, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bristol-Myers Squibb Company and Viatris Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bristol-Myers Squibb Company or Viatris Inc. Stock?

Overall, Bristol-Myers Squibb Company stock has a Value Score of 51, Growth Score of 43 and Estimate Revisions Score of 77.

Viatris Inc. stock has a Value Score of 84, Growth Score of 32 and Estimate Revisions Score of 73.

Comparing Bristol-Myers Squibb Company and Viatris Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.